Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Peled

Showing results (91-100 of 97) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 97 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Epidemiology and Infection|November 2, 2011
Recent trends in the epidemiology of non-typhoidal Salmonella in Israel, 1999-2009R Bassal, A Reisfeld, N Andorn, et al.
ESMO Open|October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinibN Peled, A Tufman, L V Sequist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumorsE Izumchenko, K Paz, D Ciznadija, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 10

Showing results (91-100 of 97) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 97 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 11, 2019
Position of an international panel of lung cancer experts on the decision for expansion of approval for pembrolizumab in advanced non-small-cell lung cancer with a PD-L1 expression level of ≥1% by the USA Food and Drug AdministrationG Mountzios, J Remon, S Novello, et al.
Epidemiology and Infection|November 2, 2011
Recent trends in the epidemiology of non-typhoidal Salmonella in Israel, 1999-2009R Bassal, A Reisfeld, N Andorn, et al.
ESMO Open|October 25, 2025
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinibN Peled, A Tufman, L V Sequist, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 24, 2021
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189D Rodríguez-Abreu, S F Powell, M J Hochmair, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 26, 2017
Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumorsE Izumchenko, K Paz, D Ciznadija, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 25, 2019
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registryJ Mazieres, A Drilon, A Lusque, et al.
ESMO Open|January 24, 2026
Global advances and future directions in lung cancer care: expert consensus and strategic prioritiesM-L Meyer, S Peters, P A Jänne, et al.
Pageof 10